Cantor Fitzgerald Comments on BCAX FY2025 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings of ($2.50) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share.

A number of other analysts have also commented on BCAX. RODMAN&RENSHAW raised Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. Stifel Nicolaus started coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price objective for the company. Morgan Stanley initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating and a $35.00 target price on the stock. TD Cowen started coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, HC Wainwright started coverage on shares of Bicara Therapeutics in a research report on Friday, December 6th. They set a “buy” rating and a $42.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $43.00.

Bicara Therapeutics Stock Down 3.1 %

Shares of BCAX opened at $11.60 on Thursday. Bicara Therapeutics has a twelve month low of $11.51 and a twelve month high of $28.09. The firm’s 50 day moving average price is $17.08.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14).

Hedge Funds Weigh In On Bicara Therapeutics

Several institutional investors have recently made changes to their positions in BCAX. RA Capital Management L.P. purchased a new stake in Bicara Therapeutics during the third quarter valued at approximately $177,169,000. FMR LLC bought a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at $57,913,000. Braidwell LP purchased a new stake in shares of Bicara Therapeutics in the 3rd quarter worth $42,219,000. Janus Henderson Group PLC bought a new position in Bicara Therapeutics in the 3rd quarter worth $30,329,000. Finally, Baker BROS. Advisors LP purchased a new position in Bicara Therapeutics during the third quarter valued at $21,225,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.